Reducing Particulate Matter-Associated Cardiovascular Health Effects for Seniors
Reducing Particulate Matter-Associated Cardiovascular Health Effects for Seniors
批准号:
10427306
负责人:
Robert Daniel Brook
金额:
$52.75万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-06 至 2024-06-30
关键词:
AccountingAcuteAddressAdrenal GlandsAdultAirAir PollutionAirborne Particulate MatterAmericanAsiaBloodBlood PressureBlood VesselsCardiovascular systemCessation of lifeChronicClinicalClinical TrialsCross-Over StudiesDataDiastolic blood pressureDouble-Blind MethodEffectivenessElderlyEnvironmentEventExposure toFaceFiltrationGlucocorticoidsGrantGuidelinesHairHealthHeart failureHospitalizationHot SpotHousingHydrocortisoneHypertensionIncidenceInsulin ResistanceInterventionIntervention StudiesLocationLong-Term EffectsLow incomeMediator of activation proteinMineralocorticoidsMorbidity - disease rateMyocardial InfarctionNIH Program AnnouncementsOutcomeParticulateParticulate MatterPathway interactionsPopulationPopulation HeterogeneityPopulations at RiskPrevention strategyPublic HealthRandomizedResidential FacilitiesResolutionRestRiskRisk FactorsSalivarySteroidsStrokeTimeTranslatingVulnerable PopulationsWorld Health Organizationair filtrationblood pressure elevationcardiometabolismcardiovascular healthcardiovascular risk factorclinically relevantcostevidence basefine particleshemodynamicshypothalamic-pituitary-adrenal axisimprovedindexingindoor airindoor particulate matterinsightinsulin sensitivitymortalitynovelnovel strategiespollutantportabilityprimary endpointprimary outcomeresidencescale upsecondary outcomesuccesstrend
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Fine particulate matter <2.5 µm (PM2.5) air pollution is the fifth leading risk factor for mortality worldwide.
Over 88 thousand deaths per year are attributable to PM2.5 in the US alone, with the largest portion from
cardiovascular (CV) causes (myocardial infarctions, strokes, heart failure). Despite improvements across the
US, PM2.5 remains above World Health Organization Air Quality Guidelines (<10 µg/m3) in numerous hot-spots
(e.g., near roadways). Therefore, it is critical to develop feasible and effective personal strategies to protect
“vulnerable” (urban/near-roadway) and “susceptible” (elderly) populations at risk from the harmful effects of
PM2.5.
Emerging trials have shown that portable indoor air filtration units (AFUs) with high-efficiency particulate
arrestance filters can reduce PM2.5 exposures by 30-50% and improve CV health endpoints (e.g., BP, vascular
function). Our recent clinical trial results confirm that even low PM2.5 levels pose significant risks to CV health
and that portable indoor air filtration units (AFUs) represent a promising preventative strategy. However, no
study has addressed whether exposure reductions and health improvements can be sustained over more
clinically relevant periods of intervention (i.e., several weeks) which are required to plausibly yield decreases in
actual CV events. In addition, the efficacy of the novel practical (i.e., less expensive and more feasible in real-
world settings) approach of using a single AFU only in the bedroom to focus on reducing nocturnal PM2.5
exposure is currently unknown.
This proposal seeks to conduct a randomized double-blind 3-way crossover intervention study (AFUs in 2
rooms vs. bedroom AFU use alone vs. sham filtration) in 50 adults living in a low-income senior residence
impacted by roadway pollutants. Specific Aims are: (1) determine if long-term, 2-room AFU usage provides
sustained reductions in PM2.5 exposure and persistent improvements in cardiometabolic outcomes; (2)
determine if nocturnal PM2.5 exposure reduction alone improves cardiometabolic outcomes; and (3)
demonstrate the key role of adrenal activation as a novel mechanism explaining PM2.5-induced cardiometabolic
changes. Our proposal will help validate the benefits of novel strategies to employ AFUs in an elderly
vulnerable population. Positive results would represent a key step in forming the evidence base required to
promote more wide-scale AFU use; in the long term, given their low cost and burden, AFU use could be up-
scaled to help protect diverse populations.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1161/circoutcomes.120.006815
发表时间:
2020-07
期刊:
Circulation. Cardiovascular quality and outcomes
影响因子:
--
作者:
[Brook RD, Levy P, Rajagopalan S]
通讯作者:
Rajagopalan S
Limitations in the Methodology Assessing Blood Pressure and the Need for Strict Exclusion Criteria-Reply.
评估血压方法的局限性和严格排除标准的必要性-答复。
DOI:
10.1001/jamainternmed.2018.7483
发表时间:
2019
期刊:
JAMA internal medicine
影响因子:
39
作者:
[Brook,RobertD, Morishita,Masako]
通讯作者:
Morishita,Masako
ACHIEVE P1 - HTN
-
批准号:10494198
-
项目类别:
-
资助金额:$69.12万
-
财政年份:2021
-
负责人:Robert Daniel Brook
-
依托单位:
ACHIEVE P1 - HTN
-
批准号:10437396
-
项目类别:
-
资助金额:$53.78万
-
财政年份:2021
-
负责人:Robert Daniel Brook
-
依托单位:
ACHIEVE P1 - HTN
-
批准号:10662512
-
项目类别:
-
资助金额:$57.77万
-
财政年份:2021
-
负责人:Robert Daniel Brook
-
依托单位:
Reducing Particulate Matter-Associated Cardiovascular Health Effects for Seniors
-
批准号:10207776
-
项目类别:
-
资助金额:$54.12万
-
财政年份:2014
-
负责人:Robert Daniel Brook
-
依托单位:
Reducing Particulate Matter-Associated Cardiovascular Health Effects for Seniors
-
批准号:10011861
-
项目类别:
-
资助金额:$57.23万
-
财政年份:2014
-
负责人:Robert Daniel Brook
-
依托单位:
COUNTERACT Supplement--ASPIRE: Air Pollution: Strategies for Personalized Intervention to Reduce Exposure
-
批准号:10218398
-
项目类别:
-
资助金额:$12.5万
-
财政年份:2011
-
负责人:Robert Daniel Brook
-
依托单位:
ASPIRE: Air Pollution: Strategies for Personalized Intervention to Reduce Exposure
-
批准号:9754146
-
项目类别:
-
资助金额:$29.85万
-
财政年份:2011
-
负责人:Robert Daniel Brook
-
依托单位:
CARDIOVASCULAR LINKAGE BETWEEN ENDOTHELIAL FUNCTION & AIR POLLUTION
-
批准号:7603730
-
项目类别:
-
资助金额:$4.41万
-
财政年份:2007
-
负责人:Robert Daniel Brook
-
依托单位:
VASCULAR TISSUE ANGIOTENSINII & ENDOTHELIAL DYSFUNCTION IN UNCOMPLICATED OBESITY
-
批准号:7376511
-
项目类别:
-
资助金额:$0.31万
-
财政年份:2006
-
负责人:Robert Daniel Brook
-
依托单位:
CARDIOVASCULAR LINKAGE BETWEEN ENDOTHELIAL FUNCTION & AIR POLLUTION
-
批准号:7376546
-
项目类别:
-
资助金额:$2.1万
-
财政年份:2006
-
负责人:Robert Daniel Brook
-
依托单位:
VASCULAR TISSUE ANGIOTENSINII & ENDOTHELIAL DYSFUNCTION IN UNCOMPLICATED OBESITY
-
批准号:7199830
-
项目类别:
-
资助金额:$6.23万
-
财政年份:2005
-
负责人:Robert Daniel Brook
-
依托单位:
ANGIOTENSIN RECEPTOR BLOCKADE IN AGE DEPENDENT ENDOTHELIAL DYSFUNCTION
-
批准号:7199820
-
项目类别:
-
资助金额:$7.67万
-
财政年份:2005
-
负责人:Robert Daniel Brook
-
依托单位:
CARDIOVASCULAR LINKAGE BETWEEN ENDOTHELIAL FUNCTION & AIR POLLUTION
-
批准号:7199869
-
项目类别:
-
资助金额:$14.62万
-
财政年份:2005
-
负责人:Robert Daniel Brook
-
依托单位:
DEPRESSION AND ENDOTHELIAL FUNCTION - DEPEND II
-
批准号:7199811
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2005
-
负责人:Robert Daniel Brook
-
依托单位:
LEPTIN IN MODULATING VASCLRTONE & ENDOTHELIAL FUNCT OBESE & NORMAL WGHT ADULT
-
批准号:7199887
-
项目类别:
-
资助金额:$2.98万
-
财政年份:2005
-
负责人:Robert Daniel Brook
-
依托单位:
Cardiovascular Linkage between Endothelial Function & AIR Pollution
-
批准号:7039842
-
项目类别:
-
资助金额:$0.76万
-
财政年份:2004
-
负责人:Robert Daniel Brook
-
依托单位:
Depression and Endothelial Function - DEPEND II
-
批准号:7039773
-
项目类别:
-
资助金额:$1.42万
-
财政年份:2004
-
负责人:Robert Daniel Brook
-
依托单位:
Angiotensin Receptor Blockade in Age Dependent Endothelial Dysfunction
-
批准号:7039783
-
项目类别:
-
资助金额:$7.52万
-
财政年份:2004
-
负责人:Robert Daniel Brook
-
依托单位:
Vascular Tissue AngiotensinII & Endothelial Dysfunction in Uncomplicated Obesity
-
批准号:7039802
-
项目类别:
-
资助金额:$10.42万
-
财政年份:2004
-
负责人:Robert Daniel Brook
-
依托单位:
海外基金